Skip to main content
. Author manuscript; available in PMC: 2017 Sep 25.
Published in final edited form as: Nat Rev Clin Oncol. 2016 Dec 29;14(6):335–346. doi: 10.1038/nrclinonc.2016.205

Table 3.

Summary results of CAR cell studies in patients with lymphoma

Centre n Conditioning therapy Infused CAR cell dose ORR (%) CR (%) PR (%)
NCI 4 FLU (25 mg/m2 × 5 days)/CY (60 mg/kg × 2 days) + iv IL-2 following CAR-cell infusion 0.3 3 × 107 CAR T cells/kg 100 0 100
NCI 11 FLU (25 mg/m2 × 5 days)/CY (60 or 120 mg/kg × 2 days) 1 5 × 106 CAR T cells/kg 89 56 33
NCI 9 FLU (30 mg/m2 × 3 days)/CY (300 mg/m2 × 3 days) 1 × 106 CAR T cells/kg 67 11 56
MSKCC 6 BEAM conditioning and autologous SCT 5 × 106 1 × 107 CAR T cells/kg 100 100 0
U Penn 23 Variable, including EPOCH, CY, bendamustine, and FLU/CY 3.7 8.9 × 106 CAR T cells/kg (median 5.8 × 106) 50 38 12
Fred Hutchinson 10 Lymphodepleting chemotherapy 2 × 105 or 2 × 106 or 2 × 107 CAR T cells/kg 67 11 56

BEAM, carmustine, etoposide, cytarabine, melphalan; CAR, chimeric antigen receptor; CR, complete response; CY, cyclophosphamide; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; FLU, fludarabine; MSKCC, Memorial Sloan Kettering Cancer Center; NCI, National Cancer Institute; ORR, overall response rate; PR, partial response; U Penn, University of Pennsylvania.